Synergistic Activation by Monoclonal Antibodies of β-Galactosidase from Genetically Defective E. Coli

  • R. J. S. Duncan


The β-galactosidase (EC proteins synthesised by certain mutant forms of Escherichia coli have little or no ability to catalyze the hydrolyses of galactosides unless activated by treatment with antibodies directed against the enzyme from a strain of E. coli not mutated at the same genetic locus1,2. This activation is usually regarded as being mediated by conformational changes in the β-galactosidase protein1,3 sometimes with the additional assumption that the enzyme protein is constrained to a single active conformation by the antibodies. The results presented here imply that the activation is not a simple correction of a conformational defect, that many distinct active states of the enzyme exist, and that the kinetic mechanism followed during catalysis differs depending on the particular active state conferred by the antibodies.


Synergistic Activation Ascitic Fluid Mutant Form Immunoglobulin Isotype Conformational Defect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    F. Celada, J. Ellis, K. Bodlund, and B. Rotman, Antibody mediated activation of a defective β-D-galactosidase, J.Exp.Med. 134:751 (1971).PubMedCrossRefGoogle Scholar
  2. 2.
    W. Messer and F. Melchers, The activation of mutant β-galactosidase by specific antibodies, in:“The Lactose Operon”, J.R. Beckwith and D. Zipser, eds., pp 305–315, Cold Spring Harbor Press. (1970).Google Scholar
  3. 3.
    F. Melchers and W. Messer, The mechanism of activation of mutant β-galactosidase by specific antibodies, Eur.J.Biochem. 35:380 (1973).PubMedCrossRefGoogle Scholar
  4. 4.
    G.R. Craven, E. Steers, and C. B. Anfinsen, Purification, composition, and molecular weight of the B-galactosidase of E. coli K12, J.Biol.Chem. 240:2468 (1965).PubMedGoogle Scholar
  5. 5.
    L.A. Herzenberg, Studies on the induction of β-galactosidase in a cryptic strain of E. coli. Biochim.Biophys.Acta. 31:525 (1959).PubMedCrossRefGoogle Scholar
  6. 6.
    J. Hewitt and E. Liew, Antigen-specific suppressor factors produced by T cell hybridomas for delayed-type hypersensitivity, Eur.J.Immunol. 9:572 (1979).PubMedCrossRefGoogle Scholar
  7. 7.
    P.J. Fraker and J.C. Speck, Protein and cell-membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a diphenylglycoluril, Biochem.Biophys.Res.Commun. 80:849 (1978).PubMedCrossRefGoogle Scholar
  8. 8.
    R.A. Roth and B. Rotman, Inactivation of normal β-D-galactosidase by antibodies to defective forms of the enzyme, J.Biol.Chem. 250:7759 (1975).PubMedGoogle Scholar
  9. 9.
    R. Duggleby, A non-linear regression program for small computers,Anal.Biochem. 110:9 (1981).PubMedCrossRefGoogle Scholar
  10. 10.
    O.M. Viratelle, J.P. Tenu, J. Garnier, and J. Yon, A preliminary study of the nucleophilic competition in β-galactosidase catalyzed reactions, Biochem.Biophys.Res.Commun. 37:1036 (1969).PubMedCrossRefGoogle Scholar
  11. 11.
    J. Hewitt, R.J.S. Duncan, and P.D. Weston, Hybridoma antibody mediated activation of β-galactosidases from genetically defective E. coli, in:“Protides of the Biological Fluids,” M. Peeters, ed., vol 29 in the press. (1981).Google Scholar
  12. 12.
    P.D. Weston and R.J.S. Duncan. Unpublished observations.Google Scholar
  13. 13.
    M. Dixon, The graphical determination of Km and Ki, Biochem.J. 129:197 (1972).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1983

Authors and Affiliations

  • R. J. S. Duncan
    • 1
  1. 1.The Wellcome Research LaboratoriesBeckenham, KentEngland

Personalised recommendations